Dr Patterson will review the background to the pharmaceutical crisis and the different ways that companies are approaching the issues. The lecture will review both the research and development and business issues facing the industry and its investors. The Pharmaceutical industry has been through a period of unprecedented growth in the last three decades, fuelled by the advances in biomedical science and an increasingly affluent Western Society. Looking forward, the picture is less rosy with reduced research and development productivity coupled with increasing pre-registration data demands from regulators and burgeoning costs. Taken together with major products losing patent protection and the need for health care costs to be kept under control, the current business model is under threat. Dr Patterson will review the background to the crisis and the different ways that companies are approaching the issues. The lecture will review both the research and development and business issues facing the industry and its investors.
All content for Pharmaceutical Industry: Past, Present and Future is the property of Oxford University and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Dr Patterson will review the background to the pharmaceutical crisis and the different ways that companies are approaching the issues. The lecture will review both the research and development and business issues facing the industry and its investors. The Pharmaceutical industry has been through a period of unprecedented growth in the last three decades, fuelled by the advances in biomedical science and an increasingly affluent Western Society. Looking forward, the picture is less rosy with reduced research and development productivity coupled with increasing pre-registration data demands from regulators and burgeoning costs. Taken together with major products losing patent protection and the need for health care costs to be kept under control, the current business model is under threat. Dr Patterson will review the background to the crisis and the different ways that companies are approaching the issues. The lecture will review both the research and development and business issues facing the industry and its investors.
Tilli Tansey, Professor of History of Modern Medical Sciences, University College London traces the evolution of the modern pharmaceutical industry from the mid nineteenth century to the final decades of the twentieth century. The strong focus on British companies is not exclusive, and a large cast of characters including manufacturers, doctors, scientists and patients are considered. Several themes are explored, including the role of innovation in relation to production technology, marketing and advertising, and in particular in pharmaceutical research and drug discovery. The impact of legislation is examined with respect to animal experimentation, standardisation and drug safety. These changes will be discussed against a background of scientific advances, clinical developments and patient expectations.
Pharmaceutical Industry: Past, Present and Future
Dr Patterson will review the background to the pharmaceutical crisis and the different ways that companies are approaching the issues. The lecture will review both the research and development and business issues facing the industry and its investors. The Pharmaceutical industry has been through a period of unprecedented growth in the last three decades, fuelled by the advances in biomedical science and an increasingly affluent Western Society. Looking forward, the picture is less rosy with reduced research and development productivity coupled with increasing pre-registration data demands from regulators and burgeoning costs. Taken together with major products losing patent protection and the need for health care costs to be kept under control, the current business model is under threat. Dr Patterson will review the background to the crisis and the different ways that companies are approaching the issues. The lecture will review both the research and development and business issues facing the industry and its investors.
